The prior year Say on Pay vote received approximately 96% support, signaling strong shareholder alignment with the compensation program. Pay structure is heavily performance-oriented: the proxy discloses that 92.5% of CEO total reported compensation was variable or at-risk (consisting of performance bonuses, performance stock awards, time-based stock awards, and stock options), far exceeding the 50-60% policy threshold for performance-based pay. The pay-for-performance alignment check also passes — MIRM's 3-year total shareholder return of +253.4% dramatically outperforms the peer group median of +23.8% by +229.6 percentage points and outperforms the XBI — SPDR S&P Biotech ETF by +186.9 percentage points, providing clear justification for above-benchmark incentive payouts; the company also has a Dodd-Frank compliant clawback policy in place.

Ernst & Young LLP has audited Mirum since the company's founding in 2018, giving it approximately 8 years of tenure — well below the 25-year threshold that would raise independence concerns. The fee table discloses only audit fees of $2.387 million with zero non-audit fees, meaning the non-audit fee ratio is 0%, far below the 50% threshold that would trigger a concern. No restatements or auditor adequacy issues were identified; Ernst & Young is a Big 4 firm appropriate for a $5.5 billion market cap company.